Drugs to beat COVID-19 Favipiravir: Glenmark Begins Phase III Trials

Glenmark Pharamacaueticls has initiated phase -3 clinical trials in India on antiviral tablets favipiravir for which it received approval from India’s drug regulator DCGI in late April.

Glenmark Pharamacaueticls is the first company in India to initiate Phase 3 clinical trials on Drugs to beat COVID-19 Favipiravir for patients in India. It is a generic version of Avigan of Fujifilm Toyama chemical co.ltd, Japan, a subsidiary of Fujifilm Corporation.

Clinical trials have commenced and over 10 leading government & private hospitals in India are being enrolled for the study. Glen mark estimates that the study would complete by July/August 2020. The formulations for the product through its in house R & D team.

Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. They believe the study results will be significantly as there is no currently any effective treatment for the virus. The data we get from the trials will point in clear direction with COVID-19 treatment and management.

Glenmark pharmaceuticals ltd said that the effort to launch a treatment for COVID-19 Patients as soon as possible and control the spread of the pandemic. They will ensure the accessibility of the product across the country if the clinical trials are successful.

ALSO READ: Why India and Nepal arguing over kalapani? – Latest Update

According to approved clinical trial protocol, 150 subjects with mild to moderate COVID-19 will be randomized in the study in 1;1 ratio to Favipiravir with standard supportive care.

Treatment duration is the maximum of 14 days and the total study duration will be a maximum of 28 days from randomization.